晨会纪要（R3） 晨会纪要 2026 年 03 月 03 日 | 市场数据 | | | | --- | --- | --- | | 指数名称 | 收盘 | 涨跌% | | 上证指数 | 4182.59 | 0.47 | | 深证成指 | 14465.79 | -0.20 | | 创业板指 | 3294.16 | -0.49 | | 科创 50 | 1464.77 | -1.56 | | 北证 50 | 1475.73 | -3.99 | | 沪深 300 | 4728.67 | 0.38 | 上证指数-沪深 300 走势图 -8% 2% 12% 22% 32% 2025-03 2025-06 2025-09 2025-12 上证指数 沪深300 | 黄红卫 | 分析师 | | --- | --- | | 执业证书编号:S0530519010001 | | | huanghongwei@hnchasing.com | | | 陈郁双 | 分析师 | | 执业证书编号:S0530524110001 | | | chenyushuang@hnchasing.com | | 晨会聚焦 一、财信研究观点 【市场策略】三 ...

获得受理的公告 证券代码：000661 证券简称：长春高新 公告编号：2026-011 长春高新技术产业（集团）股份有限公司 关于子公司 GenSci161 注射液境内生产药品注册临床试验申请 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）控股 子公司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到国家药品 监督管理局核准签发的《受理通知书》，金赛药业 GenSci161 注射液的境内生产 药品注册临床试验申请获得受理，现将有关情况公告如下： 一、药品的基本情况 产品名称：GenSci161 注射液 申请事项：境内生产药品注册临床试验 受理号：CXSL2600282、CXSL2600283 申请人：长春金赛药业有限责任公司 审批结论：经审查，决定予以受理 适应症：用于子宫内膜异位症和化脓性汗腺炎 二、药品的其它情况 GenSci161 注射液是金赛药业自主研发的一款治疗用生物制品 1 类药物，拟 用于治疗子宫内膜异位症和化脓性汗腺炎。 子宫内膜异位症是女性常见慢性系统性炎症性疾病，发病率约 ...

证券日报网讯 2月27日，长春高新在互动平台回答投资者提问时表示，公司目前获批临床的适应症是用 于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上腺皮质增 生症、特发性的原因导致的儿童小阴茎，未来如有其他达到披露标准的新情况，公司将按照法律法规要 求履行相应的披露义务。 （文章来源：证券日报） ...

证券日报网讯2月27日，长春高新（000661）在互动平台回答投资者提问时表示，公司员工情况会按照 法律法规要求在定期报告相应章节具体列示，具体请关注定期报告相关内容。 ...

证券之星消息，2月27日，生物经济（970038）指数报收于2178.02点，跌0.57%，成交7.9亿元，换手率 0.06%。当日该指数成份股中，上涨的有33家，英科医疗以5.08%的涨幅领涨，下跌的有12家，长春高 新以2.77%的跌幅领跌。 资金流向方面，生物经济（970038）指数成份股当日主力资金净流出合计2.53亿元，游资资金净流出合 计2.08亿元，散户资金净流入合计4.61亿元。成份股资金流向详情见下表： 生物经济（970038）指数十大成份股详情如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

（图片来源：摄图网） 2月25日，长春高新技术产业(集团)股份有限公司发布公告，其子公司长春金赛药业有限责任公司自主研发 的GenSci141软膏临床试验申请获得国家药品监督管理局(NMPA)批准。该药物适应症为用于改善因多种原因 导致的儿童小阴茎，这是全球首款针对儿童小阴茎的特异性治疗药物，标志着这一长期缺乏标准药物治疗的 领域迎来历史性突破。 不过，面对市场热捧，长春高新保持审慎态度。2月26日，公司方面对《每日经济新闻》记者表示："这个项 目还处于早期阶段，目前没有能对外交流的信息。"同日，长春高新董秘办相关人士进一步说明："目前该药 物只是拿到了临床试验的批准，暂未开始进行临床研究。上市时间还不确定，后续从临床试验、上市申报再 到最终获批上市还需较长时间。" 这种审慎并非多余。创新药研发素有"双十定律"之称——即耗时10年、投入10亿美元，且失败率极高。目前 GenSci141仅获批开展临床试验，距离真正的商业化落地还有临床I-III期及上市审批等多道关卡。 曾几何时，国内儿童用药长期依赖进口，从生长激素到罕见病药物，跨国药企占据绝对主导地位;如今，以 长春高新、百济神州、信达生物等为代表的创新药企， ...

【#长春高新回应儿童小阴茎专用药获批#：上市至少要三年】#儿童小阴茎专用药上市至少三年#27日， 长春高新股价开盘走低，一度跌超4%。截至发稿，长春高新报95.88元/股。对于股价走势，@中新经纬 以投资者身份致电长春高新证券部，一位工作人员回应称，"股价涨跌背后，没有特殊原因。"2月24 日，长春高新发布公告称，子公司金赛药业GenSci141软膏境内生产药品注册临床试验申请获得批准。 该药品用于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上 腺皮质增生症、特发性原因导致的儿童小阴茎。对于GenSci141软膏的研发进展，上述工作人员回应 称，基于对药物研发的通常理解，一切顺利的情况下，从临床获批到上市的周期，至少也要三年。但每 一个试验阶段都存在不确定性，都会影响到后续药品上市的时间。 转自：贝壳财经 ...

长春高新（000661.SZ）：儿科隐形赛道新突破，GenSci141开启第二增长曲线 核心观点 市场对长春高新的认知仍停留在"生长激素依赖者"，却忽视了公司在儿科罕见病领域的重磅炸弹布局。 GenSci141软膏作为全球首个针对儿童病理性小阴茎的First-in-class外用药物，近期已正式获批临床，标志着其距离 商业化更近一步。 不同于市场对存量激素业务 长春高新（000661.SZ）：儿科隐形赛道新突破，GenSci141开启第二增长曲线 核心观点 · 存量患者：中国3-12岁男性儿童存量约3.6万人。 · 年新增：每年新增病理性患儿约2100人。 市场对长春高新的认知仍停留在"生长激素依赖者"，却忽视了公司在儿科罕见病领域的重磅炸弹布局。 GenSci141软膏作为全球首个针对儿童病理性小阴茎的First-in-class外用药物，近期已正式获批临床，标志着其距离 商业化更近一步。 不同于市场对存量激素业务过度悲观的预期，我们认为：GenSci141不仅是管线的突破，更是公司商业模式的复 刻。 它具备"全球首创+罕见病刚需+儿科渠道复用+高定价权"四大核心要素，有望复刻生长激素的商业传奇。 经我们测 ...

Group 1: Automotive Industry - Stellantis, the global fourth-largest automotive manufacturer, reported a net loss of €22.3 billion (approximately ¥180.2 billion) for the year 2025, primarily due to €25.4 billion in extraordinary restructuring costs incurred in the second half of the year [1] - Despite the losses, Stellantis showed signs of recovery in the second half of 2025, with revenue growth and significantly improved cash flow compared to the first half [1] - The company's net revenue for 2025 was €153.5 billion, a slight decrease of 2% year-on-year, attributed to foreign exchange impacts and declining new car prices in the first half [1] Group 2: Pharmaceutical Industry - Changchun High-tech's subsidiary, JinSai Pharmaceutical, received approval for clinical trials of GenSci141 ointment, a drug aimed at treating male children's developmental disorders, marking a significant market opportunity as no similar products exist globally [3][4] - Following the announcement, Changchun High-tech's stock price surged over 12% within two days, reflecting strong market interest and potential for growth in the pharmaceutical sector [2] Group 3: Technology and Communication - WeChat launched a new feature allowing users to check how many chats a file has been used in, which does not duplicate storage space, addressing user concerns about storage management [6] - Meituan has applied for trademarks related to real estate, indicating a strategic move into property-related services [5] Group 4: Corporate Changes - Ctrip announced the resignation of its co-founder and president, Fan Min, along with board member Ji Qi, as part of a restructuring effort to enhance the board's professional diversity and strategic oversight capabilities [7][8] - ByteDance's valuation has risen to $550 billion, reflecting a 66% increase compared to last year's stock buyback valuation, indicating strong investor confidence in the company's growth potential [9]

Group 1 - China and the US are maintaining communication through the economic consultation mechanism, aiming for stable and sustainable development of bilateral trade relations [2] - German Chancellor Merz's visit to China resulted in over ten commercial agreements, emphasizing cooperation in AI and other advanced fields [3][51] - China has implemented export controls on Japan to prevent its militarization and nuclear ambitions, reflecting concerns over regional peace [4][52][53] Group 2 - The deployment of 11 US F-22 stealth fighters in Israel marks a significant military presence in the Middle East [5][54] - Indirect negotiations between the US and Iran have reportedly made significant progress, with further discussions scheduled [7][55] - China's AI model usage surged, surpassing the US for the first time, with a notable increase in model calls [8][56] Group 3 - New regulations for online food safety will take effect on June 1, requiring platforms to take responsibility for food safety throughout their operations [9][57] - The offshore RMB has appreciated significantly, breaking the 6.83 mark, indicating a strong upward trend in the currency [10][58] - Shanghai's gold recovery industry may soon require mandatory real-name registration to enhance security and traceability [11][59] Group 4 - Ctrip Group announced a change in leadership, with the resignation of its president and a significant increase in revenue for Q4 2025 [16][62] - The Guotou Ruijin silver fund compensation process has begun, with over 10,000 users engaging in the resolution process via an online platform [17][63] - The rumor regarding Sanzi Yang's successful backdoor listing has been officially denied, clarifying the company's current status [18][64] Group 5 - Nvidia reported record revenue for Q4 2026, driven by its data center business, which has seen substantial growth since the launch of ChatGPT [19][66] - Longcheng High-tech's new drug for treating boys' developmental issues has led to a significant increase in its stock price, reflecting market excitement [22][68] - The actual controller of Dongfang Fortune plans to donate a substantial amount of shares to Shanghai Jiao Tong University, highlighting corporate social responsibility [23][69]